BRANFORD, Conn., April 29 /PRNewswire/ -- Core Informatics announces that it has delivered an installation of their Enterprise Core LIMS product to BioRelix Pharmaceuticals of New Haven, CT. BioRelix, which started laboratory operations in late 2007, recognized the need to establish a strong data management infrastructure from the beginning. After conducting an extensive survey of the LIMS marketplace, BioRelix choose the Core LIMS.
"After our evaluation it became very clear that the Core LIMS was the best product for our needs," said Ken Blount, Director of Biology for BioRelix. "Their product provides us with an opportunity to manage data for our entire drug discovery process in a single enterprise wide system."
One of the benefits of the Core LIMS is its component-based architecture, which allows customers to choose only the components of their system that are required to meet their current needs. "As BioRelix grows and their needs change to require, for example, in-life studies, they can purchase additional components for the Core LIMS to enable that growth," said James Gregory, Chief Software Architect of Core Informatics.
About Core Informatics
Core Informatics is a software company focused on delivering state of the art, fully customized Laboratory Information Management Systems (LIMS) to customers in a variety of industries. Their signature product, The Core LIMS, is a web-based LIMS that features a component-based architecture, which provides its clients the freedom to pick and choose only the functionality relevant to their specific research. The company provides its products via three modes of delivery: LIMS appliances, hosted LIMS and enterprise LIMS.
For more information about Core Informatics, please visit www.corelims.com.
About BioRelix Pharmaceuticals
BioRelix Pharmaceuticals, Inc. is a drug discovery and development company focused on identifying new anti-infective drug treatments. BioRelix is building a portfolio of anti-infective products based on novel patented RNA targets, termed RiboSwitches, which were identified in the laboratory of BioRelix co-founder, Ronald Breaker Ph.D., Howard Hughes Investigator and Henry Ford II Professor at Yale University. BioRelix investors include CHL Medical Partners, New Leaf Venture Partners, Aisling Capital, Novartis Venture Fund, Elm Street Ventures and Alexandria Real Estate Equities.
For more information about BioRelix Pharmaceuticals, please visit www.biorelix.com.
CONTACT: Jim Gregory, +1-203-643-8099, email@example.com
Web site: http://www.corelims.com/